OBJECTIVES: THIS SESSION WILL UPDATE ATTENDEES ON RECENT EFFORTS TO REVITALIZE AND REINVIGORATE CLINICAL TRIALS IN SOLID ORGAN TRANSPLANTATION. IN THIS SESSION, ATTENDEES WILL:
1. LEARN ABOUT THE ROLE OF PRIVATE PUBLIC PARTNERSHIPS WITH GOVERNMENT APPROVAL AGENCIES IN FORGING NEW PATHWAYS OF DRUG APPROVAL NOT PREVIOUSLY UTILIZED
2. IDENTIFY AND LEARN ABOUT CLINICAL TRIAL ENDPOINTS DEVELOPED THROUGH CONSENSUS OF INVESTIGATORS AND PATIENTS
3. LEARN ABOUT THE DESIGN OF FUTURE TRIALS THAT MAY INCORPORATE NEW ENDPOINTS SUCH AS PATIENT REPORTED OUTCOMES, BIOMARKERS, COMPOSITE END POINTS, AND SPECIFIC HIGH RISK GROUPS
Roslyn B. Mannon, United States
Professor of Medicine and Surgery, Director of Transplant Research, University of Alabama Birmingham
The Transplant Therapeutics Consortium: Update on Progress and Goals
Read Profile
Allison Tong, Australia
Associate Professor, Sydney School of Public Health, University of Sydney
Solidifying Endpoints in Clinical Trials: SONG Tx Initiative
Read Profile
Stefan Schneeberger, Austria
Head, Transplant and Hepatobiliary Surgery; Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University
Challenges Involved in Developing New Endpoints for Clinical Trials
Read Profile